Central government issues a major document: Opportunities for IVD development have arrived!

Against the backdrop of testing price reform and hospital cost control, the policy side has clearly released three major incremental signals: First, domestic substitution in key areas such as clinical mass spectrometry, high-end molecular diagnostics, and core raw materials will extend toward underlying technologies; Second, AI-empowered integrated smart laboratory solutions are expected to accelerate their implementation; Third, new precision diagnostics scenarios such as early tumor screening and genetic testing for rare diseases will gain smoother channels for translating results into applications. The focus of industry competition will further shift toward hardcore innovative enterprises that "can solve real clinical problems and create sustainable clinical value."